Middle East and Africa miRNA Sequencing and Assay Market Growth and Analysis by 2027

The Middle East and Africa miRNA sequencing and assay market is expected to reach US$ 22.00 million by 2027 from US$ 8.71 million in 2019; it is estimated to grow at a CAGR of 12.4% from 2020 to 2027.

The widening application range of microRNAs and rise in funding for genomics research. However, challenges associated with the delivery, efficacy, and specificity of miRNA-based therapeutics hinder the market growth.

miRNA is partially complementary to messenger RNA (mRNA) and its main function is to downregulate gene expression. Since their discovery they have emerged as vital regulators of important cellular functions. Being involved in the process of differentiation, they play a crucial role as a useful marker in identifying cell types. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. Thus, there is extensive research being conducted to identify new miRNAs. Furthermore, discovery regarding the role of miRNAs in disease development have made miRNAs a key target of novel therapeutic approaches. Several miRNA-targeted therapeutics against the diseases such as cancer and hepatitis have reached the clinical phase. For instance, Santaris Pharma has developed a therapeutic molecule named Miravirsen that targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in the Phase II clinical trial. Therefore, the growing range of applications of miRNAs is driving the growth of the miRNA sequencing and assay market. Similarly, rise in funding of genomic research to identify new molecules to diagnose and treat diseases across Middle East and Africa, is fuelling the market growth.

Countries in the Middle East regions are experiencing serious effects of the COVID-19 pandemic. The initial phases of lockdown in various countries affected the supply of many instruments and consumables in these regions. Due to surging COVID-19 cases, demand for novel diagnostic tests is on rise in the Middle East, and research activities have resulted in higher adoption of miRNA sequencing and assay procedures in this region. Hence, the ongoing pandemic is positively impacting the miRNA sequencing and assay market in the Middle East and Africa.

 

Middle East and Africa miRNA Sequencing and Assay Market Segmentation

By Product

• Library Preparation
• Consumables

By Technology

• Sequencing by Synthesis
• Nanopore
• Ion Semiconductor Sequencing

By End User

• Research Institute
• Academia
• CRO

By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East and Africa

Company Profiles

• Illumina, Inc
• THERMO FISHER SCIENTIFIC INC.
• QIAGEN
• Perkin Elmer, Inc.
• Takara Bio Inc.
• New England Biolabs
• Norgen Biotek Corp
• TriLink BioTechnologies Inc.
• Lexogen GmbH
• Oxford Nanopore Technologies

Middle East and Africa miRNA Sequencing and Assay Report Scope